Syngene Announces Q1 FY27 Results: Revenue at Rs 736 Cr; Operating EBITDA at Rs 91 Cr
Syngene International Limited today released its financial results for the first quarter of fiscal year 2027 (Q1 FY27). The company reported revenue from operations at Rs 736 Crore, while operating EBITDA stood at Rs 91 Crore.The quarterly performance showed shifts compared to Q1 FY26. Revenue from Operations was Rs 736 Cr in Q1 FY27, down from Rs 875 Cr in Q1 FY26, representing a 16% decrease. Operating EBITDA for the quarter was Rs 91 Cr, compared to Rs 206 Cr in Q1 FY26, marking a 56% decline. The operating EBITDA margin stood at 12%, down from 24% in the previous year's corresponding period.
The company reported PAT before exceptional items of Rs 1 Cr, significantly lower than the Rs 87 Cr recorded in Q1 FY26. After accounting for an exceptional item, PAT was (Rs 9) Cr.
Management Perspective and Strategic Focus
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene, stated that she accepted the role as part of reshaping the company's next phase of growth. She expressed confidence in the management team to execute with discipline while positioning the Company for sustainable growth, driven primarily by CDMO (Contract Development and Manufacturing Organization) and AI-led advanced services.Siddharth Mittal, Managing Director and CEO, addressed the challenges faced during the quarter, stating a commitment to working closely with the Board and leadership team. He outlined immediate priorities including sharpening commercial execution, strengthening delivery across businesses, and building a more agile, cost-competitive organization. The company will continue investing in CDMO, AI, innovation, and differentiated scientific capabilities.
Deepak Jain, Chief Financial Officer, explained that performance was primarily impacted by the lack of offtake from a major biologics client and forex hedge losses, partially mitigated by ongoing cost optimization initiatives. He noted that despite these headwinds, the company maintains a strong balance sheet, enabling investment in strategic priorities such as infrastructure, technology platforms, automation, and emerging modalities.
While expecting degrowth in the first half of the fiscal year, management indicated that business momentum is anticipated to improve in the second half, leading to single-digit revenue degrowth in rupee terms for the full year and EBITDA margins stabilizing in the mid-20s.
Operational and Governance Updates
Syngene reported several key operational advancements and made updates regarding its Board composition:Key Business Highlights:
- Collaboration with THSTI: Syngene signed a Memorandum of Understanding (MoU) with BRIC-Translational Health Science and Technology Institute (THSTI), an institute under the Biotechnology Research & Innovation Council. This partnership focuses on early and late-phase clinical development, translational research, and bioanalytical sciences, including First-in-Human (FIH) and Phase I programs.
- AI Platform Advancement: The company enhanced Syn.AI, its AI-enabled scientific platform for drug discovery acceleration. During the quarter, capabilities were developed for gigascale virtual screening and advanced AI-driven de novo design of novel drug candidates.
- Sustainability Ranking: Syngene was recognized by TIME Magazine and Statista in the "World's Most Sustainable Companies 2026" ranking. From over 5,800 companies across 43 countries, Syngene ranked among the world's top 750 most sustainable companies.
Board Updates:
- Dr. Kush Parmar stepped down as an Independent Director after serving since 2021 and previously being a member of the Risk Management Committee and the Science and Technology Committee.
- Dr. Vijaya Chandru was appointed as an Independent Director, bringing over 25 years of leadership in deep-tech innovation, with expertise spanning AI, computational biology, genomics, and CRISPR-based biotechnology.
- Dr. Arun Chandavarkar was appointed as an Independent Director, having previously served as CEO and Joint MD of Biocon Limited.
Quarterly Financial Data Summary (All figures in Indian Rupees Crore)
The financial metrics for Q1 FY27 compared to Q1 FY26 are detailed below:| Metric | Q1 FY27 | Q1 FY26 | YoY Change (%) |
|---|---|---|---|
| Revenue from Operations | 736 | 875 | -16% |
| Operating EBITDA | 91 | 206 | -56% |
| Operating EBITDA margin | 12% | 24% | |
| PAT before exceptional item | 1 | 87 | -99% |
| PAT after exceptional item | (9) | 87 | -110% |
A more granular view of the financial performance, including EBITDA and EBIT figures across multiple quarters, is available in the financial tables provided by the company.
SYNGENE Stock Price Movement
Today, shares of Syngene International Limited edged higher to close at ₹414.25 after gaining 1.06% in trading. The stock successfully navigated an intraday range between a low of ₹406 and a high of ₹417.5, with over 1.2 million shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.